Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

CARsgen Approved to Start China Trials of BCMA CAR-T Candidate

publication date: Mar 12, 2019

CARsgen Therapeutics, a Shanghai CAR-T company, was approved to start China clinical trials of its fully human BCMA (B-Cell Maturation Antigen) CAR-T cell therapy in patients with relapsed/refractory multiple myeloma (rrMM). In December 2018, CARsgen presented positive early data from the candidate. With 14 patients reporting, the treatment produced a 100% overall response rate (79% were very good or complete responses). CARsgen has developed 11 CAR-T candidates, of which three have started clinical trials and two have filed INDs. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital